跳至主要内容
临床试验/NCT00704223
NCT00704223已完成不适用

Observational Study on Safety and Efficacy in Subjects Using NovoMix® 70 (Biphasic Insulin Aspart) for Treatment of Type 2 Diabetes Mellitus

Novo Nordisk A/S0 个研究点目标入组 619 人开始时间: 2008年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
619
主要终点
number of major and minor hypoglycaemic events and adverse events

研究概览

简要总结

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes
  • HbA1c over 7%
  • No contraindication with NovoMix® 70

排除标准

  • Type 1 diabetes
  • Subjects participating in a clinical trial or another observational study
  • Subjects under previous basis-bolus insulin therapy
  • Women who are pregnant, breast feeding and women of child bearing capacity who are not using any reliable contraceptive method

研究组 & 干预措施

A

干预措施: biphasic insulin aspart (Drug)

结局指标

主要结局

number of major and minor hypoglycaemic events and adverse events

时间窗: 3 months

次要结局

  • HbA1c(3 months)
  • PPBG(3 months)
  • FBG(3 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Observational Study to Evaluate the Safety and... | 临床试验